Kyzatrex, also known as maralixibat, is a medication approved in Europe for specific medical conditions. Its primary indication is for the treatment of cholestatic pruritus in patients with Alagille syndrome [1].
What is Alagille Syndrome?
Alagille syndrome is a rare genetic disorder that can affect multiple organs, including the liver, heart, eyes, and skeleton. Liver involvement typically manifests as a reduced number of bile ducts, leading to cholestasis, a condition where bile flow is impaired. This can cause a buildup of bile acids in the body, resulting in symptoms such as pruritus (itching) [1].
How Does Kyzatrex Work?
Kyzatrex is an ileal bile acid transporter (IBAT) inhibitor. By inhibiting this transporter in the intestine, it reduces the reabsorption of bile acids from the gut back into the liver. This leads to decreased levels of bile acids in the liver, which can alleviate cholestatic pruritus [1].
When Did Kyzatrex Receive European Approval?
Kyzatrex received marketing authorization in the European Union on January 26, 2024 [1]. The approval was granted by the European Commission, following a positive opinion from the European Medicines Agency (EMA) [1].
Who Manufactures Kyzatrex?
Kyzatrex is developed and manufactured by Mirum Pharmaceuticals, Inc [1].
What is the Clinical Trial Data Supporting Kyzatrex's Approval?
The European approval was based on data from clinical trials, including the ICONIC study, which demonstrated a statistically significant reduction in pruritus and serum bile acid levels in pediatric patients with Alagille syndrome [1].
Are There Any Other Uses for Maralixibat?
While Kyzatrex is approved in Europe for Alagille syndrome, maralixibat is also being investigated for other conditions involving cholestatic pruritus, such as progressive familial intrahepatic cholestasis (PFIC) [2]. Further research and regulatory decisions will determine its availability for these other indications.